The effectiveness of treatment with enoxaparin in lichen planus

Abstract

ÖZETAmaç: Heparin analoglarının düşük dozlarının antiproliferatif ve immünmodülatör etkilerinin olduğu bilinmektedir. Bu çalışmanın amacı; liken planusta düşük doz enoxaparinin etkinliğini değerlendirmektir. Gereç ve yöntem:Liken planus tanısı alan 21 hasta 12 hafta boyunca tedavi edildi. Hastalara her hafta 3 mg enoxaparin subkutan enjeksiyonla yapıldı. Etki ve güven-lik verileri kaydedildi. Bulgular:Tam iyileşme hastaların 15' inde (%71), belirgin düzelme 4' ünde (%19) tespit edildi. Hastaların 2'sinde (%9) tedaviye yanıt alınmadı. Tedavi sonucunda en iyi yanıt, liken planusun akut generalize tipinde görüldü.Sonuç: Sonuç olarak enoxaparin tedavisinin liken planusta etkili bir tedavi seçeneği olabileceği kanaatine varıldı.Anahtar kelimeler: Liken planus, enoxaparin, tedavi ABSTRACT Objectives: As it is known, the low doses of Heparin's analogues have the antiproliferative and immunomodulator activities. This research aims to evaluate the activity of enoxaparin by using the low doses. Materials and methods:21 patients with lichen planus diagnosis have been cured within 12 weeks. 3 mg of enoxaparin has been used for subcutaneus injection to all of patients weekly. The efficient and reliable data has been saved. Results:The perfect recovery has been observed 15 (71%) of 21 patients, the distinct recovery has been observed 4 (19%) of 21 patients. The treatment has not given response on 2 (9%) of 21 patients. The best score has been received on acute generalized type of Lichen Planus. Conclusions:As the result; it has been reported that enoxaparin treatment can be an effective choice in Lichen Planus medication. J Clin Exp Invest 2011; 3(2): 172-173

Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports

“…They reported disease improvement in 26 out of 31 patients. Ucmak and co-workers reported distinctive recovery of the disease in 71% of patients (15 out of 21) treated with enoxaparin for 12 weeks ( Uçmak et al, 2012 ). Neville et al (2007) demonstrated a sustained clinical response to enoxaparin in a patient with recalcitrant ulcerative LP resistant to oral corticosteroids.…”